Key Developments: Auxilium Pharmaceuticals Inc (AUXL.O)

AUXL.O on Nasdaq

26 Dec 2014
Price Change (% chg)

$0.35 (+1.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Endo International PLC announces termination of HSR act waiting period in connection with proposed acquisition of Auxilium Pharmaceuticals Inc
Wednesday, 19 Nov 2014 07:30am EST 

Endo International plc and Auxilium Pharmaceuticals Inc:Says that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act) in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on Nov. 18.Expects the deal to close in the first quarter of 2015, subject to pending customary closing conditions.Says it would acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction valued at about $2.6 bln.Termination of the waiting period satisfies a condition to the closing of the transaction.Completion of the transaction remains subject to approval by Auxilium stockholders and certain other customary closing conditions.  Full Article

QLT Inc announces merger with Auxilium Pharmaceuticals, Inc. terminates for superior proposal
Thursday, 9 Oct 2014 06:47am EDT 

QLT Inc:Says that it has been advised by Auxilium Pharmaceuticals, Inc. that Auxilium's board of directors has reviewed an offer from Endo International plc to acquire all of the issued and outstanding shares of Auxilium.Says after consulting with its financial advisors and outside legal counsel, has determined that the Endo Proposal is a superior proposal under the terms of the Agreement and Plan of Merger among QLT, Auxilium, QLT Holding Corp., and QLT Acquisition Corp., dated June 25, 2014.Says accordingly, Auxilium has delivered a notice of termination of the Merger Agreement and has, in accordance with the Merger Agreement, agreed to concurrently pay to QLT a termination fee in the amount of $28.4 million.  Full Article

Endo International PLC To acquire Auxilium Pharmaceuticals Inc
Thursday, 9 Oct 2014 06:30am EDT 

Endo International PLC and Auxilium Pharmaceuticals Inc:Have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.The boards of directors of both companies have unanimously approved the transaction, which is valued at $2.6 billion, including the repayment and assumption of debt.The per share consideration represents a premium of 55 pct to Auxilium's closing price on Sept. 16.The transaction is expected to close in the first half of 2015.Citi served as financial advisor to Endo, Lazard provided an independent fairness opinion and Sullivan & Cromwell LLP served as legal advisor.Deutsche Bank served as lead financial advisor, Morgan Stanley served as financial advisor and Willkie Farr & Gallagher LLP and Morgan, Lewis & Bockius served as legal advisors to Auxilium.  Full Article

Vivus and Auxilium announce FDA approval of STENDRA sNDA
Thursday, 18 Sep 2014 06:00am EDT 

Vivus Inc and Auxilium Pharmaceuticals Inc:Says U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for STENDRA A (avanafil).  Full Article

QLT Inc provides update on merger with Auxilium Pharmaceuticals Inc
Wednesday, 17 Sep 2014 07:05am EDT 

QLT Inc:Says Auxilium Pharmaceuticals receives an unsolicited offer from Endo International plc to acquire all of the issued and outstanding shares of Auxilium.Auxilium further advised QLT that it is reviewing the Endo Proposal, and has not withdrawn, modified, withheld, changed or qualified its recommendation with respect to the proposed merger with QLT.Merger Agreement continues in full force and effect.  Full Article

Endo International PLC delivers proposal to acquire Auxilium Pharmaceuticals
Tuesday, 16 Sep 2014 04:45pm EDT 

Endo International PLC:Says it has delivered a proposal to acquire all of the outstanding shares of Auxilium Pharmaceuticals, Inc. for a per share consideration of $28.10 in a cash and stock transaction valued at $2.2 bln.Endo's proposal represents a premium of 31 pct to Auxilium's closing price on Sept. 16 and a 40 pct premium to the average closing price of Auxilium shares for the previous 30 days.Under the terms of the proposal, consideration would include an about equal mix of cash and Endo stock.Endo intends to fund the transaction through a combination of existing cash on hand and debt financing.  Full Article

Auxilium Pharmaceuticals Inc to reduce headcount about 30 pct
Tuesday, 9 Sep 2014 05:00pm EDT 

Auxilium Pharmaceuticals Inc:Company is taking steps to reduce its costs and more fully support company's goal to drive earnings growth and build shareholder value.Identified annual cost savings totaling greater than $75 mln, which includes reducing headcount by about 30 pct.Says majority of reducing headcounts will be immediate, realigning commercial organization from three into two sales forces, focusing R&D efforts and expenditures and improving manufacturing efficiency.Company anticipates substantial completion of the restructuring by the end of 2014, with the full $75 mln run-rate achieved by mid-year 2015.  Full Article

Auxilium Pharmaceuticals Inc appoints Andrew Saik Chief Financial Officer
Monday, 11 Aug 2014 06:00am EDT 

Auxilium Pharmaceuticals Inc:Andrew Saik will be appointed Chief Financial Officer, effective Aug. 18.  Full Article

Auxilium Pharmaceuticals Inc reaffirms FY 2014 guidance
Thursday, 7 Aug 2014 06:01am EDT 

Auxilium Pharmaceuticals Inc:Expects FY 2014 net revenues of between $380 mln and $420 mln.Anticipates FY 2014 net income loss to be breakeven or a $15 million loss.FY 2014 revenue of $397 mln and net income $(10) mln - Thomson Reuters I/B/E/S.  Full Article

Auxilium Pharmaceuticals to merge with canadian biotechnology company QLT
Thursday, 26 Jun 2014 07:00am EDT 

Auxilium Pharmaceuticals Inc and QLT Inc:Enters into a definitive agreement under which Auxilium plans to merge with QLT.Transaction is expected to drive shareholder value creation by accelerating Auxilium's ongoing transformation into a diversified North American specialty biopharmaceutical company.Under the terms of the agreement, a wholly-owned subsidiary of QLT will be merged with and into Auxilium.QLT will remain incorporated in British Columbia, Canada, and will be renamed "New Auxilium.".Combined organization will be led by Auxilium's current leadership team and will maintain Auxilium's current offices in Chesterbrook, Pennsylvania.  Full Article

Endo profit beats estimates on strong generic drug sales

Nov 5 - Endo International Plc, which is acquiring Auxilium Pharmaceuticals Inc, reported a better-than-expected quarterly profit due to a nearly 74 percent jump in sales of its generic drugs in the United States.

Search Stocks